Hims & Hers Health, Inc. Class A Common Stock (HIMS)
44.77
+2.22 (5.22%)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care
The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery.
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also exist.
Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game.
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced two new programs dedicated to serving its customers in even more personalized ways, encouraging customers to play an active role in the decisions and choices that shape their healthcare experience.
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Monday, February 24, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.
